Home › Skin Cancer › California › San Francisco
Skin Cancer clinical trials in San Francisco, CA
3 studies for Skin Cancer are looking for participants at sites in and around San Francisco (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Recruiting
- Zuckerberg San Francisco General, San Francisco
- Kaiser Foundation Research Institute, San Francisco
- University of San Francisco, San Francisco
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
RecruitingPhase 2/3
- University of California San Francisco - Helen Diller Family Comprehensive Cancer Center, San Francisco
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, San Francisco
About Skin Cancer
Try ABCDE on a mole to check for signs of skin cancer: Asymmetry, Border, Color, Diameter, Elevation. Learn more on advanced detection and treatments.
More about Skin Cancer on MedlinePlus
Skin Cancer trials in other cities
- Boston, MA8 studies
- Tampa, FL7 studies
- New York City, NY7 studies
- Washington, DC6 studies
- Pittsburgh, PA6 studies
- Salt Lake City, UT6 studies
- Rochester, MN5 studies
- Houston, TX5 studies
- Los Angeles, CA5 studies
- St. Louis, MO4 studies
- Orlando, FL4 studies
- Atlanta, GA4 studies
Other studies in San Francisco
- Prostate Cancer45 studies
- Breast Cancer43 studies
- Non-Small Cell Lung Cancer36 studies
- Cancer (all types)35 studies
- Heart Failure29 studies
- Metastatic Cancer28 studies
- Lung Cancer22 studies
- Melanoma22 studies
- Pancreatic Cancer20 studies
- Ovarian Cancer19 studies
- Colorectal Cancer18 studies
- Cardiovascular Disease18 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.